A druggable conformational switch in the c-MYC transactivation domain

Dilraj Lama,Thibault Vosselman,Cagla Sahin,Judit Liaño-Pons,Carmine P. Cerrato,Lennart Nilsson,Kaare Teilum,David P. Lane,Michael Landreh,Marie Arsenian Henriksson

DOI: https://doi.org/10.1038/s41467-024-45826-7

IF: 16.6

2024-02-29

Nature Communications

Abstract:Abstract The c- MYC oncogene is activated in over 70% of all human cancers. The intrinsic disorder of the c-MYC transcription factor facilitates molecular interactions that regulate numerous biological pathways, but severely limits efforts to target its function for cancer therapy. Here, we use a reductionist strategy to characterize the dynamic and structural heterogeneity of the c-MYC protein. Using probe-based Molecular Dynamics (MD) simulations and machine learning, we identify a conformational switch in the c-MYC amino-terminal transactivation domain (termed coreMYC) that cycles between a closed, inactive, and an open, active conformation. Using the polyphenol epigallocatechin gallate (EGCG) to modulate the conformational landscape of coreMYC, we show through biophysical and cellular assays that the induction of a closed conformation impedes its interactions with the transformation/transcription domain-associated protein (TRRAP) and the TATA-box binding protein (TBP) which are essential for the transcriptional and oncogenic activities of c-MYC. Together, these findings provide insights into structure-activity relationships of c-MYC, which open avenues towards the development of shape-shifting compounds to target c-MYC as well as other disordered transcription factors for cancer treatment.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop effective treatment strategies for c - MYC, an oncogene that is activated in more than 70% of human cancers. The intrinsically disordered nature of the c - MYC protein enables it to regulate numerous biological pathways, but at the same time, it also greatly limits the efforts in cancer treatment targeting its function. Specifically, the focus of the paper is on identifying a conformational switch in the amino - terminal transcriptional activation domain of c - MYC (called coreMYC), which cycles between a closed (inactive) and an open (active) conformation. By using the polyphenol epigallocatechin - 3 - gallate (EGCG) to regulate the conformational landscape of coreMYC, the study shows that inducing the closed conformation can impede its interactions with transformation/transcription domain - associated protein (TRRAP) and TATA - box - binding protein (TBP), which are crucial for the transcriptional and oncogenic activities of c - MYC. Therefore, this study aims to open up new avenues for the development of shape - shifting compounds targeting c - MYC and other disordered transcription factors for cancer treatment by revealing the structure - activity relationship of c - MYC.

Through molecular dynamics simulations and machine - learning techniques, the paper discovered a key conformational switch in c - MYC and verified the effect of EGCG on this conformational change through biophysical and cell experiments. This not only deepens the understanding of the structure and function of c - MYC but also provides theoretical basis and technical support for the design of drugs targeting c - MYC.